米国保健医療システムにおけるワルファリン患者自己管理 (PSM) の障壁の克服:実施試験試験プロトコル
Heeseung Hong1,2, Aaron S Wilson1, Aubrey E Jones1,2
1University of Utah College of Pharmacy, Salt Lake City, Utah.
medRxiv : the preprint server for health sciences
|September 2, 2025
まとめ
ウォルファリン治療の患者自己管理 (PSM) は,効果的ではあるが,米国では十分に活用されていない. この研究は,米国保健医療システムにおけるワルファリン管理と患者のアウトカムを改善するためのPSM戦略を実装しています.
科学分野:
- 薬理学について
- 医療サービス研究
- 実施科学
背景:
- ウォルファリンは狭い治療指数薬であり,定期的に国際標準比率 (INR) を監視する必要があります.
- 現在の臨床ベースのINRモニタリングは,しばしばワーファリンの管理が最適でない結果をもたらします.
- ウォルファリンの患者自己管理 (PSM) は優れた有効性を示しているが,米国ではめったに使われない.
研究 の 目的:
- ウォルファリン患者の自己管理 (PSM) を米国保健医療システムで実施する.
- 特定された障壁に対処し,PSMの採用のためのレバレッジファシリテーター.
- PSM戦略の実施と効果を評価する.
主な方法:
- タイプIIIハイブリッド実施効果試験の設計が採用されます.
- 4つのサイトで150人の成人患者がPSMの実施に参加します.
- 統合された実施研究枠組みと品質実施枠組みは,迅速なサイクル研究方法論のサポートで戦略を導くでしょう.
主要な成果:
- この研究では,PSMの実施戦略の成果を評価する.
- PSMの臨床成果は,RE-AIMの枠組み (リーチ,有効性,採用,実施,維持) を用いて評価されます.
- 倫理委員会の承認は,すべての参加サイトから得られます.
結論:
- この研究は,米国の抗凝固サービスにおけるPSMの実現可能性を実証することを目的としています.
- ウォルファリンの管理と患者のケアを 改善できるでしょう
- 成果は出版物,会議,公開ツールキットを通じて広められる.
関連する概念動画
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Venous Thrombosis IV: Nursing Management
22
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
22
Anticoagulant Drugs: Low-Molecular-Weight Heparins
889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889
Peripheral Artery Disease IV: Nursing Management
43
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
43
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
644
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
644


